BSECompany Update1d ago · 17 Nov 2026, 11:18 pm

Please find enclosed intimation

Cipla Ltd · 500087

✦ AI SummaryRegulatory

Cipla Ltd has received a 'No Action Indicated' classification from the USFDA for an inspection at its InvaGen manufacturing facility in Hauppauge, Long Island, New York, USA. The inspection was conducted from October 19 to 22, 2026, and the USFDA's communication dated November 17, 2026, classified the inspection as NAI.

Analysis Scores

Earnings Impact5/10
Growth Catalyst3/10
Governance Concern2/10
Regulatory Risk8/10
Balance Sheet Risk4/10
Liquidity Impact6/10
Market Sentiment5/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Cipla Ltd - 500087 - Update On USFDA Inspection At Invagen Manufacturing Facility In Hauppauge, Long Island, New York, USA

Attachments (1)

📄

df40f4ad-c335-43ae-9d24-699bf1273a86.pdf

pdf

Download →
View document text
17 November, 2026 (1) BSE Limited (2) National Stock Exchange of India Limited Listing Department, Listing Department Phiroze Jeejeebhoy Towers, Exchange Plaza, 5th floor, Dalal Street, Plot no. C/1, G Block, Mumbai 400 001 Bandra Kurla Complex, Bandra (East), Mumbai - 400 051 Scrip Code: 500087 Scrip Code: CIPLA (3) SOCIETE DE LA BOURSE DE LUXEMBOURG Societe Anonyme 35A Boulevard Joseph II, L-1840 Luxembourg Dear Sir/Madam, Sub: Update on USFDA inspection at InvaGen manufacturing facility in Hauppauge, Long Island, New York, USA Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and further to our intimation dated 23 October 2026 regarding the inspection conducted by the United States Food and Drug Administration (USFDA) at the manufacturing facility of InvaGen Pharmaceuticals Inc. (InvaGen), a wholly owned subsidiary of the Company, located in Hauppauge, Long Island, New York, USA, from 19 October 2026 to 22 October 2026, we hereby notify that the USFDA, vide its communication dated 17 November 2026, has classified the aforementioned inspection as No Action Indicated (NAI). Please take the above information on record. Yours faithfully, For Cipla Limited Rajendra Chopra Company Secretary Prepared by: Chirag Hotchandani Cipla Ltd. Regd. Office - Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai-400 013, India P +91 22 24826000 F +91 22 24826120 W www.cipla.com E-mail contactus@cipla.com Corporate Identity Number L24239MH1935PLC002380